In the remaining 18 patients, CeD diagnosis was established by meeting the ESPGHAN criteria (TTG-IgA levels > 10 × ULN) and therefore did not undergo duodenal biopsy. This evidence concerns the gene CD79A and cranioectodermal dysplasia.